
    
      The primary objective of this prospective, multicenter, double-blind, randomized,
      placebo-controlled, parallel group, Phase 3 study is to determine the effect of oral
      lucerastat monotherapy on neuropathic pain in subjects with Fabry disease (FD) through daily
      collection of patient-reported outcomes with an electronic diary.
    
  